BiotechTube

human Mesenchymal Stem Cell (MSC) infusion therapy

Phase 1UNKNOWN
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aging Well

Conditions

Aging Well, Regenerative Medicine

Trial Timeline

Apr 15, 2020 โ†’ Apr 14, 2022

NCT ID
NCT04174898

About human Mesenchymal Stem Cell (MSC) infusion therapy

human Mesenchymal Stem Cell (MSC) infusion therapy is a phase 1 stage product being developed by CytoMed Therapeutics for Aging Well. The current trial status is unknown. This product is registered under clinical trial identifier NCT04174898. Target conditions include Aging Well, Regenerative Medicine.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04174898Phase 1UNKNOWN

Competing Products

20 competing products in Aging Well

See all competitors
ProductCompanyStageHype Score
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
52
HRS-1738 InjectionJiangsu Hengrui MedicinePhase 1/2
41
fluvastatinNovartisPhase 2
52
Ranolazine + Placebo to match ranolazineGilead SciencesApproved
84
CP-424,391PfizerPhase 2
51
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 + Nivolumab Injection [Opdivo]Bristol Myers SquibbPhase 1
32
injectable poly-L-lactic acidSanofiApproved
84
Gadobutrol (Gadavist/Gadovist, BAY86-4875)BayerPre-clinical
20
Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882)BayerPhase 3
74
Iopromide (Ultravist, BAY86-4877)BayerPre-clinical
20
Gadoquatrane (BAY1747846)BayerPhase 3
74
BAY86-4367 + BAY86-4367BayerPhase 1
30
GBCAsBayerPre-clinical
20
Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3
74
BAY1747846BayerPhase 1
30
Gadoterate (Dotarem/Clariscan) + Gadobutrol (Gadavist/Gadovist, BAY86-4875)BayerApproved
82
Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + GadoteridolBayerPhase 3
74
Gadobutrol (Gadovist, BAY86-4875)BayerPre-clinical
20
F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102)BayerPhase 1
30
Gadopentetate dimeglumine (Magnevist, BAY86-6661)BayerPhase 3
74

Other Products from CytoMed Therapeutics

Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ฮณฮด T Cells (CTM-N2D)Phase 1
25
Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cellPhase 1
25